Mayne Pharma GroupASX:MYX +7.53%51 Median PS Value is A$7.61 as of Jun. 26, 2026, which is 100% below its 10-year median of 0.62. GuruFocus rates ASX:MYX with a GF Score™ of 51/100 and a GF Value™ of A$5.31 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 70 Medical Distribution companies, Mayne Pharma Group ranks better than 91.43% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Mayne Pharma Group's Median PS Value or its related term are showing as below:
ASX:MYX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31 Med: 0.62 Max: 1.05
Current: 0.34
During the past 13 years, the highest Price to Median PS Value of Mayne Pharma Group was 1.05. The lowest was 0.31. And the median was 0.62.
ASX:MYX's Price-to-Median-PS-Value is ranked better than 91.43% of 70
companies
in the Medical Distribution industry
Industry Median: 0.79
vs ASX:MYX: 0.34
Mayne Pharma Group (ASX:MYX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Mayne Pharma Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.57
/
7.61
=
0.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group Median PS Value Related Terms
Mayne Pharma Group Median PS Value Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MYX vs MCK, COR, CAH: Median PS Value Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Price-to-Median-PS-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.4924.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mayne Pharma Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.099.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (ASX:MYX) has a Median PS Value of A$7.61 as of Jun. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Mayne Pharma Group and its competitors. This is 1127% above median its historical median of 0.62. Over the past decade, Mayne Pharma Group's Median PS Value has ranged from 0.31 to 1.05. According to the industry distribution chart, Mayne Pharma Group ranks #6 out of 70 companies in the Medical Distribution industry, placing it in the top 8.6%.
Is Mayne Pharma Group's Median PS Value too high?
Mayne Pharma Group's current Median PS Value of A$7.61 is 1127% above median its 10-year median of 0.62. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 1.05. Based on the distribution chart, Mayne Pharma Group ranks #6 out of 70 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Median PS Value compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #6 out of 70 companies for Median PS Value. This places Mayne Pharma Group in the top 9% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.79. Historically, Mayne Pharma Group's own Median PS Value has ranged from 0.31 to 1.05 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Distribution company?
The median Median PS Value among Medical Distribution companies is 0.79, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Median PS Value is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Median PS Value is A$7.61, which is 1127% above median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current Median PS Value is A$7.61, which is 1127% above median its 10-year median of 0.62. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current Median PS Value is A$7.61 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
Median PS Value: A$7.61 (1127% above median its 10-year median of 0.62)
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
